Pharsight

Adlarity is owned by Corium.

Adlarity contains Donepezil Hydrochloride.

Adlarity has a total of 7 drug patents out of which 0 drug patents have expired.

Adlarity was authorised for market use on 11 March, 2022.

Adlarity is available in system;transdermal dosage forms.

Adlarity can be used as a method of transdermal delivery of donepezil for treating mild, moderate and severe dementia of the alzheimer's type.

The generics of Adlarity are possible to be released after 11 August, 2038.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10016372	CORIUM	Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery	Jul, 2037 (14 years from now)
US11103463	CORIUM	Methods for treating alzheimer's disease with donepezil transdermal system	Jul, 2037 (14 years from now)
US9993466	CORIUM	Donepezil transdermal delivery system	Jul, 2037 (14 years from now)
US10300025	CORIUM	Donepezil transdermal delivery system	Jul, 2037 (14 years from now)
US10307379	CORIUM	Donepezil transdermal delivery system	Jul, 2037 (14 years from now)
US10835499	CORIUM	Systems and methods for long term transdermal administration	May, 2038 (15 years from now)
US10966936	CORIUM	Systems comprising a composite backing and methods for long term transdermal administration	Aug, 2038 (15 years from now)